Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

European Journal of Radiology

Volumn 84, Issue 7, 2015, Pages 1259-1268

  Nishino, Mizuki ^a   Tirumani, Sree H ^a   Ramaiya, Nikhil H ^a   Hodi, F Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer; Drug toxicity; Immunotherapy; Oncologic imaging; Tumor response assessment

Indexed keywords

IMMUNOMODULATING AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DERMATITIS; ENTEROCOLITIS; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE RESPONSE; LYMPHADENOPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIOLOGIST; RADIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYROIDITIS; TUMOR VOLUME; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; REGULATORY T LYMPHOCYTE; TRENDS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84930181050     PISSN: 0720048X     EISSN: 18727727     Source Type: Journal    
DOI: 10.1016/j.ejrad.2015.03.017     Document Type: Review

References (60)

1. G.J. Freeman, A.J. Long, Y. Iwai, K. Bourque, T. Chernova, and H. Nishimura Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 7 2000 1027 1034
2. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736
3. J.F. Brunet, F. Denizot, M.F. Luciani, M. Roux-Dosseto, M. Suzan, and M.G. Mattei A new member of the immunoglobulin superfamily - CTLA-4 Nature 328 6127 1987 267 270 10.1038/328267a0
4. G.J. Freeman, J.G. Gribben, V.A. Boussiotis, J.W. Ng, V.A. Restivo Jr., and L.A. Lombard Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation Science 262 5135 1993 909 911
5. Y. Ishida, Y. Agata, K. Shibahara, and T. Honjo Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death EMBO J 11 11 1992 3887 3895
6. F.S. Hodi, and D.E. Fisher Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma Nat Clin Pract Oncol 5 12 2008 696 697 10.1038/ncponc1259
7. F.S. Hodi, M.C. Mihm, R.J. Soiffer, F.G. Haluska, M. Butler, and M.V. Seiden Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 8 2003 4712 4717 10.1073/pnas.0830997100
8. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, and J.B. Haanen Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723 10.1056/NEJMoa1003466
9. J. Weber, J.A. Thompson, O. Hamid, D. Minor, A. Amin, and I. Ron A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 17 2009 5591 5598 10.1158/1078-0432.ccr-09-1024
10. J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, and L. Thomas Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study Lancet Oncol 11 2 2010 155 164 10.1016/s1470-2045(09)70334-1
11. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, and W.H. Sharfman Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 10 2014 1020 1030 10.1200/JCO.2013.53.0105
12. C. Robert, A. Ribas, J.D. Wolchok, F.S. Hodi, O. Hamid, and R. Kefford Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117 10.1016/S0140-6736(14)60958-2
13. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, and A.M. Lesokhin Nivolumab plus ipilimumab in advanced melanoma N Engl J Med 369 2 2013 122 133 10.1056/NEJMoa1302369
14. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, and R. Kefford Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 2 2013 134 144 10.1056/NEJMoa1305133
15. F.S. Hodi, and G. Dranoff The biologic importance of tumor-infiltrating lymphocytes J Cutan Pathol 37 Suppl. 1 2010 48 53 10.1111/j.1600-0560.2010.01506.x
16. J.D. Wolchok, F.S. Hodi, J.S. Weber, J.P. Allison, W.J. Urba, and C. Robert Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma Ann N Y Acad Sci 1291 1 2013 1 13 10.1111/nyas.12180
17. J.D. Wolchok, A. Hoos, S. O'Day, J.S. Weber, O. Hamid, and C. Lebbe Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 15 23 2009 7412 7420 10.1158/1078-0432.CCR-09-1624
18. M. Nishino, A. Giobbie-Hurder, M. Gargano, M. Suda, N.H. Ramaiya, and F.S. Hodi Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements Clin Cancer Res 19 14 2013 3936 3943 10.1158/1078-0432.CCR-13-0895
19. M. Nishino, J.P. Jagannathan, K.M. Krajewski, K. O'Regan, H. Hatabu, and G. Shapiro Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST AJR Am J Roentgenol 198 4 2012 737 745 10.2214/AJR.11.7483
20. Y. Bronstein, C.S. Ng, P. Hwu, and W.J. Hwu Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy AJR Am J Roentgenol 197 6 2011 W992 W1000 10.2214/ajr.10.6198
21. K.N. O'Regan, J.P. Jagannathan, N. Ramaiya, and F.S. Hodi Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy AJR Am J Roentgenol 197 2 2011 W241 W246 10.2214/AJR.10.6032
22. K.W. Kim, N.H. Ramaiya, K.M. Krajewski, A.B. Shinagare, S.A. Howard, and J.P. Jagannathan Ipilimumab-associated colitis: CT findings AJR Am J Roentgenol 200 5 2013 W468 W474 10.2214/AJR.12.9751
23. G.Y. Ku, J. Yuan, D.B. Page, S.E. Schroeder, K.S. Panageas, and R.D. Carvajal Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival Cancer 116 7 2010 1767 1775 10.1002/cncr.24951
24. K.W. Kim, N.H. Ramaiya, K.M. Krajewski, J.P. Jagannathan, S.H. Tirumani, and A. Srivastava Ipilimumab associated hepatitis: imaging and clinicopathologic findings Investig New Drugs 31 4 2013 1071 1077 10.1007/s10637-013-9939-6
25. J. Wolchok How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma Ann Oncol 23 Suppl 8 2012 viii15 viii21 10.1093/annonc/mds258
26. F.S. Hodi, D.A. Oble, J. Drappatz, E.F. Velazquez, N. Ramaiya, and N. Ramakrishna CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS Nat Clin Pract Oncol 5 9 2008 557 561 10.1038/ncponc1183
27. C.G. Drake, E. Jaffee, and D.M. Pardoll Mechanisms of immune evasion by tumors Adv Immunol 90 2006 51 81 10.1016/s0065-2776(06)90002-9
28. R. Kim, M. Emi, and K. Tanabe Cancer immunoediting from immune surveillance to immune escape Immunology 121 1 2007 1 14 10.1111/j.1365-2567.2007.02587.x
29. C. Zielinski, S. Knapp, C. Mascaux, and F. Hirsch Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer Ann Oncol 24 5 2013 1170 1179 10.1093/annonc/mds647
30. S.M. Ansell, A.M. Lesokhin, I. Borrello, A. Halwani, E.C. Scott, and M. Gutierrez PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma N Engl J Med 2014 10.1056/NEJMoa1411087
31. D.S. Chen, B.A. Irving, and F.S. Hodi Molecular pathways: next-generation immunotherapy - inhibiting programmed death-ligand 1 and programmed death-1 Clin Cancer Res 18 24 2012 6580 6587 10.1158/1078-0432.ccr-12-1362
32. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 4 2012 252 264 10.1038/nrc3239
33. T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, and T. Honjo A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application Nat Immunol 14 12 2013 1212 1218 10.1038/ni.2762
34. E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, and A.J. van den Eertwegh Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol 15 7 2014 700 712 10.1016/S1470-2045(14)70189-5
35. T.J. Lynch, I. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, and R. Chacko Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 17 2012 2046 2054 10.1200/jco.2011.38.4032
36. R.A. Madan, M. Mohebtash, P.M. Arlen, M. Vergati, M. Rauckhorst, and S.M. Steinberg Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 5 2012 501 508 10.1016/S1470-2045(12)70006-2
37. K. Margolin, M.S. Ernstoff, O. Hamid, D. Lawrence, D. McDermott, and I. Puzanov Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 5 2012 459 465 10.1016/S1470-2045(12)70090-6
38. S.L. Topalian, F.S. Hodi, J.R. Brahmer, S.N. Gettinger, D.C. Smith, and D.F. McDermott Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 26 2012 2443 2454 10.1056/NEJMoa1200690
39. N.A. Rizvi, J. Mazieres, D. Planchard, T.E. Stinchcombe, G.K. Dy, and S.J. Antonia Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial Lancet Oncol 16 3 2015 257 265 10.1016/s1470-2045(15)70054-9
40. A. Snyder, V. Makarov, T. Merghoub, J. Yuan, J.M. Zaretsky, and A. Desrichard Genetic basis for clinical response to CTLA-4 blockade in melanoma N Engl J Med 371 23 2014 2189 2199 10.1056/NEJMoa1406498
41. R.S. Herbst, J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, and M.S. Gordon Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 7528 2014 563 567 10.1038/nature14011
42. V.A. Boussiotis Somatic mutations and immunotherapy outcome with CTLA-4 blockade in melanoma N Engl J Med 371 23 2014 2230 2232 10.1056/NEJMe1413061
43. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
44. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 2009 228 247 10.1016/j.ejca.2008.10.026
45. M. Nishino, J.P. Jagannathan, N.H. Ramaiya, and A.D. Van den Abbeele Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know AJR Am J Roentgenol 195 2 2010 281 289 10.2214/AJR.09.4110
46. J.J. Erasmus, G.W. Gladish, L. Broemeling, B.S. Sabloff, M.T. Truong, and R.S. Herbst Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response J Clin Oncol 21 13 2003 2574 2582 10.1200/jco.2003.01.144
47. M. Nishino, M. Guo, D.M. Jackman, P.J. DiPiro, J.T. Yap, and T.K. Ho CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool Acad Radiol 18 1 2011 54 62 10.1016/j.acra.2010.08.021
48. B. Zhao, L.P. James, C.S. Moskowitz, P. Guo, M.S. Ginsberg, and R.A. Lefkowitz Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer Radiology 252 1 2009 263 272 10.1148/radiol.2522081593
49. B. Zhao, Y. Tan, D.J. Bell, S.E. Marley, P. Guo, and H. Mann Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals Eur J Radiol 82 6 2013 959 968 10.1016/j.ejrad.2013.02.018
50. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1 1981 207 214
51. M. Nishino, H. Hatabu, B.E. Johnson, and T.C. McLoud State of the art: response assessment in lung cancer in the era of genomic medicine Radiology 271 1 2014 6 27 10.1148/radiol.14122524
52. M. Nishino, M. Gargano, M. Suda, N.H. Ramaiya, and F.S. Hodi Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab? J Immunother Cancer 2 2014 17 10.1186/2051-1426-2-17
53. O. Bohnsack, A. Hoos, and K. Ludajic Adaptation of the immune-related response criteria: irRECIST ESMO 2014 Abstract 4958
54. A.D. Smith, S.N. Shah, B.I. Rini, M.L. Lieber, and E.M. Remer Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy AJR Am J Roentgenol 194 6 2010 1470 1478 10.2214/ajr.09.3456
55. H. Choi, C. Charnsangavej, S.C. Faria, H.A. Macapinlac, M.A. Burgess, and S.R. Patel Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 13 2007 1753 1759 10.1200/jco.2006.07.3049
56. R.S. Benjamin, H. Choi, H.A. Macapinlac, M.A. Burgess, S.R. Patel, and L.L. Chen We should desist using RECIST, at least in GIST J Clin Oncol 25 13 2007 1760 1764 10.1200/jco.2006.07.3411
57. M.R. Gray, S. Martin del Campo, X. Zhang, H. Zhang, F.F. Souza, and W.E. Carson 3rd Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab Radiology 270 2 2014 425 434 10.1148/radiol.13130776
58. J.S. Weber, K.C. Kahler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 21 2012 2691 2697 10.1200/jco.2012.41.6750
59. G. Berthod, R. Lazor, I. Letovanec, E. Romano, L. Noirez, and J. Mazza Stalder Pulmonary sarcoid-like granulomatosis induced by ipilimumab J Clin Oncol 30 17 2012 e156 e159 10.1200/jco.2011.39.3298
60. K.J. Carpenter, R.D. Murtagh, H. Lilienfeld, J. Weber, and F.R. Murtagh Ipilimumab-induced hypophysitis: MR imaging findings Am J Neuroradiol 30 9 2009 1751 1753 10.3174/ajnr.A1623